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ABSTRACT 
Between January 1982 and August 1989, cadaveric renal transplantation was performed in 22 
patients 65 years old or older. Mean recipient age was 68 years (range 65 to 73 years). There were 
17 men and 5 women. Additional risk factors included retransplantation (3 patients), high (greater 
than 30%) panel reactive antibody (4) and diabetes (1). All patients received cyclosporine as part 
of the immunosuppressive regimen. The 3-year actuarial patient and allograft survival rates were 
89% and 71 %, respectively. There were 6 graft losses due to chronic rejection (2 patients), renal 
vein thrombosis (1), myocardial infarction (1), withdrawal of immunosuppression because of sepsis 
(1) and primary nonfunction (1). Of the 16 patients with a functioning graft 12 currently have a 
serum creatinine of less than 2.0 mg./dl. These results suggest that cadaveric renal transplantation 
is an acceptable form of treatment for patients older than 65 years with end stage renal disease. 
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Of 28,944 new Medicare patients with end stage renal disease 
accepted for dialysis in 1985, 10,285 (35.5%) were 65 years old 
or older. I However, in the same year only 57 (0.8%) of the 6,910 
transplants performed were in recipients in this age group. 1 
The reluctance to perform transplantation in these patients is 
due partly to the belief that the risks of transplantation out-
weigh the advantages. This assumption is based to a large 
extent on studies that were performed in the 1970s, before the 
advent of cyclosporine.2• 3 However, since the introduction of 
cyclosporine and the subsequent decrease in steroid require-
ments, there has been improved graft and patient survival in 
this recipient age group (table 1). We evaluate the role of renal 
transplantation in the management of end stage renal failure 
in patients older than 65 years. 
MATERIAL AND METHODS 
Between January 1982 and August 1989, cadaveric renal 
transplantation was performed in 22 patients 65 years old or 
older (mean age 68 years). The causes of renal failure were 
hypertension in 5 patients, glomerulonephritis in 5, pyelone-
phritis in 2, Wegener's granulomatosis in 1, intravenous con-
trast-induced nephropathy in 1, polycystic kidney disease in 1, 
gouty nephropathy in 1, interstitial nephritis in 1, insulin-
dependent diabetes in 1 and unknown in 3. There were 17 men 
and 5 women. Three patients were undergoing retransplanta-
tion. Panel reactive antibody was greater than 30% in 4 pa-
tients. 
All men underwent a voiding cystometrogram performed as 
part of the pretransplant evaluation. Ultrasound of the gall-
bladder has become a routine part of this evaluation since 1988, 
and elective pretransplant cholecystectomy is performed if 
calculi are present. Cardiac evaluation consisted of a stress 
thallium and/or MUGA scan and cardiac catheterization was 
performed when these were abnormal. In 7 patients a stress 
thallium test was performed and 6 of these underwent a cardiac 
catheterization before transplantation. One of these patients 
underwent coronary angioplasty before transplantation. No 
coronary artery bypass procedures were done. Additional risk 
factors for transplantation are outlined in table 2. 
The minimal transplant requirements were ABO compatibil-
ity and a negative lymphocytotoxic crossmatch on current sera. 
Accepted for publication August 2, 1991. 
No attempt was made to match for HLA-A, B or DR antigens 
and there was no formal transfusion policy during this period. 
A total of 16 patients received cyclosporine plus prednisone 
and 6 received triple therapy (cyclosporine, azathioprine and 
prednisone). Rejection was treated with high dose steroids. One 
patient received OKT3 for steroid resistant rejection. Actuarial 
patient and allograft survival, and statistical analysis were 
calculated using BMDP software. 
RESULTS 
Patient survil.lal. The 1 and 3-year actuarial patient survival 
rates were identical at 89% (see figure). Followup ranged from 
5 months to 7 years (median 27 months). There were 2 qeaths. 
One patient died of a myocardial infarction after sepsis from a 
perforated sigmoid diverticulum. A 73-year-old man had a 
history of myocardial infarction, an ejection fraction of 28% 
and significant coronary artery disease that was not surgically 
correctable. The allograft never functioned and he died of a 
myocardial infarction 2 months after transplantation. 
Graft survil.lal. The 2-year actuarial allograft survival was 
73% (see figure). Six grafts were lost due to rejection in 3, renal 
vein thrombosis in 1, death from myocardial infarction in 1 
and primary nonfunction in 1. 
Surgical complications. Surgical complications occurred in 10 
patients and resulted in 1 death and 2 allograft losses (table 3). 
Rejection. Acute rejection episodes occurred in 9 patients 
(40%),8 of whom (89%) responded to either steroids or OKT3. 
Immunosuppression was discontinued in the remaining patient 
because of sepsis, which occurred after attempted ureteral 
repair (an injury that was sustained during lymphocele drain-
age). Two patients lost the allografts to chronic rejection. 
Medical complications. Medical complications are shown in 
table 4. Two patients had fatal myocardial infarctions 40 and 
60 days after transplantation, respectively. These 2 patients 
previously demonstrated significant coronary disease on car-
diac catheterization that was considered unsuitable for surgical 
correction. One patient who had cytomegalovirus pneumonia 
suffered a steroid resistant rejection episode that responded to 
OKT3. He subsequently lost the graft to chronic rejection. 
DISCUSSION 
The introduction of cyclosporine and the subsequent use of 
lower doses of steroids have resulted in improved patient and 
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TABLE 1. Results of renal transplantation in older patients 
Recipient Age I·Yr. Pt. I·Yr. Grafi Reference No. Pts. Survival Survival (yrs.) (%) (%) 
Fauchald et aI' Older than 60 122 67 87 
Fehrman et aI' Older than 65 55 71 63 
Tapson et al6 Older than 60 13 74' 61 
Roza et al8 Older than 65 17 91 81 
Murie et ai' Older than 55 56 87 73 
Jordan et al" Older than 56 67 88 70 
Korb et altO Older than 55 24 82 70 
Present series Older than 65 22 89 71 
• 2·year survival. 
TABLE 2. Additional risk factors in renal transplant recipients older 
than 65 years 
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graft survival in renal transplantation. Fehrman et al reported 
~ and 3-year actuarial patient and graft survival rates of 71 %, 
:)7%,63% and 49%, respectively, in 55 recipients older than 65 
years.· Murie et al reported I-year patient and allograft survival 
rates of 87% and 73 % in 63 patients older than 55 years.5 These 
researchers failed to show any significant difference in allograft 
survival compared to younger recipients. Tapson et al reported 
a 74% 2-year patient survival rate and that 8 of 13 allografts 
(61 %) were functioning at a mean of 15 months after trans-
plantation.6 Others have reported good results in terms of 
patient and allograft survival (table 1).7-10 Our results of 89% 
I-year actuarial patient and 71% I-year actuarial allograft 
survival compare favorably with what has been reported re-
cently. Of the 16 kidneys still functioning 12 have serum 
creatinine levels of less than 2 mg./dl. The 2 deaths in this 
group occurred in patients with known but surgically uncor-
rectable coronary artery disease. Of the 6 grafts that failed 4 
were lost within the first 6 months and all had failed by 1 year . 
The improvement in patient and allograft survival noted may 
be attributable partly to the introduction of cyclosporine. In 
1971 Simmons et aI, using azathioprine and prednisone, re-
ported I-year patient and allograft survival rates of 40% and 
20%, respectively, in patients older than 45 years.3 In the same 
era Delmonico et al reported I-year patient and allograft sur-
vival rates of 57% and 50%, respectively, in patients older than 
51 years.2 These lower survival rates reported from the pre-
cyclosporine era were attributed largely to the high dose of 
steroids used. In the series reported by Fehrman et al 17 
patients were treated with azathioprine and steroids, and these 
patients had 1 and 3-year allograft survival rates of 59% and 
41 % compared to 65% and 54% in 38 cyclosporine treated 
patients.4 
Death with a functioning transplant is a major cause of graft 
failure in elderly patients. The chief causes of death are cardi-
ovascular disease and infection. These are inherent problems 
in this population of patients. Among 17 patients older than 65 
years reported on by Roza et all0 grafts were functioning at 3 
to 28 months.8 One kidney was lost to chronic rejection and 6 
patients died with a functioning graft: 1 of infection and 5 of 
cardiovascular disease. In the series reported by Tapson et al 
10 of 13 patients had a functioning graft 15 months after 
transplantation, 1 had primary nonfunction and the other 4 
died with a functioning graft.6 
The role of invasive pretransplant cardiac assessment is 
debatable. Jordan et al performed cardiac catheterization on 
all patients older than 55 years. 9 However, only 4 of these 67 
patients required coronary revascularization before transplan-
tation. Of the 3 coronary deaths 2 occurred in patients with 
minimal or no coronary artery disease. Howard et al performed 
stress thallium testing on 16 patients older than 65 years who 
had no cardiac symptoms before transplantation. ll Of these 
patients 8 underwent cardiac catheterization based on these 
results but none required an operation. One patient with angina 
had cardiac catheterization and required coronary bypass sur-
gery before transplantation. Four patients died of cardiovas-
cular disease in the current series. Of our 22 patients 7 under-
went a stress thallium test because of clinical symptoms and 6 
had coronary arteriography. Only 1 patient had angioplasty 
preoperatively as a result of these studies with a successful 
outcome. 
As reported by others,12 we found a low incidence (3 allo-
grafts, or 13%) of allograft loss secondary to rejection. This low 
incidence of graft loss secondary to rejection occurred despite 
TABLE 3. Surgical complications, management and outcome 
Complication 
Cholecystitis 
Ogilvie's syndrome 
Retroperitoneal hematoma 
Lymphocele 
Renal artery thrombosis 
Sigmoid colon perforation 
No. Pts. 
2 
Management (No.) 
Cholecystectomy 
Colostomy (1), colon· 
oscopy (1) 
Observation 
Ureteral injury, sepsis 
Allograft nephrectomy 
Colostomy drainage 
Excellent 
Excellent 
Outcome 
Excellent 
Immunosuppression stopped, 
graft rejected 
Pt. died of mvocardial in· 
farction at "10 days 
Sepsis. myocardial infarc· 
tion. pt. died at 40 days 
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TABLE 4. Medical complications and outcome management 
Complication No. Pts. Management Outcome 
Infection: 
Urinary tract infection 
Bacterial pneumonia 
Pneumocystis pneumonia 
Cytomegalovirus pneumonia 
Herpes: 
Zoster 
Laryngitis 
Cardiovascular: 
Myocardial infarction 
Miscellaneous: 
Nephrotic syndrome 
Steroid-induced diabetes 
mellitus 
Gastritis 
6 
3 
2 
2 
1 
2 
the fact that HLA matching was not an important selection 
criterion in this series. With the use of cyclosporine many 
single center studies, including our own, currently report no 
effect of HLA matching or mismatching on renal transplant 
outcome.13-IS Other reports of multicenter studies indicate a 
beneficial effect of matching. 16 However, this may partly reflect 
results from the pre-cyclosporine era. More recent data would 
suggest that matching is of benefit primarily for 6-antigen 
matched kidneys.17 Regardless of matching, older patients may 
be less immunocompetent and, therefore, less likely to reject 
the grafts. 
Historical comparison of survival statistics in end stage renal 
disease treatment programs is confounded by several issues. 
The results of transplantation in general have improved during 
the last decade due to increased sophistication of patient care, 
and the use of safer and more effective immunosuppression. 
Also, it is difficult to identify the selection bias inherent in 
most programs. Our patient and graft survival rates are com-
parable with those reported in other series (table 1). An alter-
native to renal transplantation is hemodialysis. Patient survival 
on dialysis is equivalent to that with transplantation. The 
European Dialysis and Transplant Association report of 1984 
showed a 2-year actuarial survival of 71 % for 60 to 69-year-old 
and 60% for 70 to 79-year-old patients on hemodialysis. 18 These 
results are comparable to the rates in the aforementioned 
transplant series (table 1).4-10 Given that survival percentage is 
satisfactory with either form of therapy, quality of life may be 
more important in choosing treatment modality. Westlie et al 
reported a detailed retrospective analysis of mortality, morbid-
ity and life satisfaction in 157 patients 70 years old or older 
who had started hemodialysis up to April 1983.19 For patients 
who started dialysis after 1976 the 3-year survival rate was 
50%. Quality of life was considered to be high. From the same 
institution, Husebye et al reported a prospective followup study 
in 1987 on 79 patients who had been interviewed in 1983."° At 
that time (1987) 54 % of the 79 patients had died. Despite the 
optimism of the earlier 1983 report, 43% of the deaths followed 
voluntary withdrawal from dialysis, perhaps a reflection of the 
quality of life on dialysis. Analysis showed that psychosocial 
and not physical factors were prognostically important. The 
patients in this later series were apparently unselected, with 
less than 1% of all candidates being considered unfit for di-
alysis. 
No formal assessment of the quality of life has been done in 
our study. However, no patient has chosen to discontinue 
therapy after transplantation. Compliance with medications is 
good and our impression is that patients are generally satisfied. 
Patients are considered for transplantation at the University 
of Pittsburgh once they are referred by their attending nephrol-
ogist. Patients are rarely rejected because they are considered 
medically unfit for transplantation. As would be expected, this 
group of patients has a high incidence of significant risk factors. 
However, a striking difference between this population and 
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Acyclovir 
Acyclovir 
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Antacids 
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Resolved without sequelae 
Resolved without sequelae 
Lost graft to chronic rejection 
Resolved without sequelae 
Resolved without sequelae 
Died 
Stsble 
Resolved without sequelae 
Resolved without sequelae 
younger transplant recipients is the incidence of insulin-de-
pendent diabetes mellitus. Approximately 30% of all transplant 
recipients at our center are diabetics. Nevertheless, only 1 of 
22 patients older than 65 years had insulin-dependent diabetes 
mellitus as a cause of the renal failure in this series. Presum-
ably, most diabetics have end stage renal disease at a younger 
age and, therefore, they undergo transplantation earlier. 
In conclusion, these data support an integrated approach to 
the management of renal failure in elderly patients, that is 
either continuous ambulatory peritoneal dialysis, hemodialysis 
or transplantation may be appropriate for the individual patient 
at a particular time. Certainly, renal transplantation should 
not be denied on the basis of patient age alone. In fact, it may 
well be the treatment of choice for older patients in terms of 
survival and quality of life. 
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